Including variables like disease duration, other relevant biomarkers (e.g., C-reactive protein, erythrocyte sedimentation rate), and patient-reported outcomes would allow the model to capture a more comprehensive picture of the factors influencing treatment response in autoimmune diseases.34 This evidence concerns the gene CRP and autoimmune disease.